MoonLake Immunotherapeutics (MLTX) Interest Expenses (2022 - 2026)

MoonLake Immunotherapeutics' Interest Expenses history runs 6 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 525.0% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $8.1 million (up 593.38% YoY), while the FY2025 annual figure was $7.2 million, down 70.93% from the prior year.
• Interest Expenses for Q1 2026 stood at $2.3 million, up from $2.2 million in the prior quarter.
• The five-year high for Interest Expenses was $25.6 million in Q2 2025, with the low at $657.0 in Q1 2022.
• The 5-year median for Interest Expenses is $212418.0 (2023), against an average of $2.3 million.
• The sharpest annual moves came in 2022 and 2025: Interest Expenses slumped 99.42% in 2022, then jumped 12265.74% in 2025.
• MoonLake Immunotherapeutics' Interest Expenses stood at $33757.0 in 2022, then jumped by 412.32% to $172945.0 in 2023, then surged by 48.38% to $256612.0 in 2024, then jumped by 752.65% to $2.2 million in 2025, then grew by 5.12% to $2.3 million in 2026.
• Business Quant data shows MLTX's Interest Expenses at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $3.2 million in Q3 2025.